Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
WIRE - Novel Treatments in Renal Cell Cancer
- Status
- RECRUITING
- Phase
- PHASE2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.
- Status
- UNKNOWN
- Phase
- PHASE2
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
- Status
- COMPLETED
- Phase
- PHASE2
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC
- Status
- WITHDRAWN
- Phase
- PHASE3